PHAXIAM Therapeutics SA

PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.

P HAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences

PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences

PHAXIAM Therapeutics (NASDAQ: PHXM ) stock is taking off on Thursday despite a lack of news from the biopharmaceutical company. There haven't been any press releases or filings with the Securities and Exchange Commission (SEC) that explain why PHXM stock is up today.

News for PHAXIAM Therapeutics SA Stock (PHXM)